Merck pays Moderna $250M to continue Keytruda, cancer vaccine combo studies
After nearly six years of working together, Merck and Moderna are taking the next step in their cancer vaccine partnership.
Merck is opting into a deal to “jointly develop and commercialize” one of Moderna’s personalized cancer shots in combination with the blockbuster drug Keytruda, the companies announced Wednesday. As part of the option, Merck will pay Moderna $250 million to advance the combo, and the companies will share costs and profits equally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.